Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · brain-umap@2

BS_M4NVX721

Ganglioglioma

ba96a0ec-ed6e-5121-a964-7775b80ac5c2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
Ganglioglioma
cancer_type_detailed
—
subtype
—
cancer_type
Ganglioglioma
age_years
14.189
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PANCREAS_BETA_CELLS+0.431
  • INFLAMMATORY_RESPONSE+0.397
  • KRAS_SIGNALING_UP+0.382
  • KRAS_SIGNALING_DN+0.380
  • ALLOGRAFT_REJECTION+0.378
  • COAGULATION+0.375
  • MYOGENESIS+0.371
  • HEDGEHOG_SIGNALING+0.369
  • ESTROGEN_RESPONSE_EARLY+0.354
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340

Top 10 suppressed

  • E2F_TARGETS-0.602
  • G2M_CHECKPOINT-0.596
  • MYC_TARGETS_V2-0.571
  • MYC_TARGETS_V1-0.537
  • DNA_REPAIR-0.462
  • UNFOLDED_PROTEIN_RESPONSE-0.381
  • MITOTIC_SPINDLE-0.378
  • WNT_BETA_CATENIN_SIGNALING-0.242
  • PROTEIN_SECRETION-0.183
  • TGF_BETA_SIGNALING-0.178

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1BS_YB2RXRHT
brain-umap@2
pilocytic astrocytoma—0.939
2MDT-AP-1124
medullo-epn-umap@date-based
MedMedulloblastoma0.929
3BS_3XY76V8T
brain-umap@2
Ganglioglioma—0.918
4BS_KQ6ZW085
brain-umap@2
DNET—0.914
5MDT-AP-1254
medullo-epn-umap@date-based
MedMedulloblastoma0.913
6BS_680K119G
brain-umap@2
Ganglioglioma—0.908
7MDT-AP-2381
medullo-epn-umap@date-based
MedMedulloblastoma0.903
8ERR2598266
medullo-epn-umap@date-based
fetalfetal0.898
9BS_044XZ8ST
brain-umap@2
pilocytic astrocytoma—0.895
10ERR2598313
medullo-epn-umap@date-based
fetalfetal0.892

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 38 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PANCREAS_BETA_CELLS0.431Cobimetinib— uncovered
INFLAMMATORY_RESPONSE0.397Idelalisib— uncovered
KRAS_SIGNALING_UP0.382Inavolisib— uncovered
KRAS_SIGNALING_DN0.380Remibrutinib— uncovered
ALLOGRAFT_REJECTION0.378Idelalisib— uncovered
COAGULATION0.375Binimetinib— uncovered
MYOGENESIS0.371Inavolisib— uncovered
HEDGEHOG_SIGNALING0.369Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.354Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.340Inavolisib— uncovered
COMPLEMENT0.304Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.300Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.267Inavolisib— uncovered
APICAL_SURFACE0.266Temsirolimus— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.259Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.249Remibrutinib— uncovered
BILE_ACID_METABOLISM0.247Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.247Inavolisib— uncovered
ANGIOGENESIS0.246Remibrutinib— uncovered
INTERFERON_GAMMA_RESPONSE0.246Idelalisib— uncovered